Two trisaccharide spacer glycosides, p-trifluoroacetamidophenylethyl 3-O-(2-acetamido-2-deoxy-α-D-galactopyranosyl) — 2 — O — (α-l-fucopyranosyl)-β-d-galactopyranoside and p-trifluoroacetamidophenylethyl 2-O-(α-l-fucopyranosyl)-3-O-(α-d-galactopyranosyl)-β-d-galactopyranoside, corresponding to the human blood group A and B determinants, were synthesized. A key fucosylgalactosyl disaccharide derivative was glycosylated with galactos-aminyl or galactosyl donors, respectively. Dimethyl(thiomethyl)sulfonium tetrafluoroborate was used for thioglycoside activation in all but one coupling reaction. The small scale procedure was further developed for use in a large scale (10–100 g final product) synthesis. Large scale syntheses of some crystalline thioglycoside building blocks are also described.
No takes yet. Share an insight, caveat, or question.
Åberg et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: